Disbursement of homeopathy? : the decision "can wait" a little, believes Agnès Buzyn

Faced with & quot; urgency & quot; to manage the heatwave, Agnès Buzyn estimated this Thursday that & nbsp; the decision of a possible deferral of homeopathy can wait.


Faced with the "urgency" of managing the heatwave, Agnès Buzyn said Thursday that the decision of a possible derogation of homeopathy can wait.

Health Minister Agnès Buzyn said Thursday that the government's decision on whether or not homeopathy could be deferred could wait a bit, given the "urgency" of managing the heatwave.

The Transparency Commission of the High Health Authority on Wednesday adopted a final opinion on the subject that should be made public only Friday morning. This opinion, according to Libération , advocates the end of reimbursement by the Sécu of homeopathic products for lack of proven effectiveness. "I have not received the opinion of the High Health Authority.Today my urgency is to manage the heatwave and its impact, I think that the decision can wait a few more days," said Agnès Buzyn on France 2 .

Pro-reimbursement events planned in Paris and Lyon

"Decisions on drug disbursement can be taken a few days or weeks after the opinion of the High Health Authority.I recall that for anti-Alzheimer drugs the decision was made almost a year after the opinion" of HAS, said the minister. She has repeatedly stated that she would follow the advice of the Transparency Commission of the HAS. Labs, homeopaths and users have launched a media campaign supported by elected officials, "My homeo, my choice", with a petition that claims for the moment more than a million signatures. They called for demonstrations, in Paris on the Esplanade des Invalides and Lyon Place de la Comedie, Friday at 10:30.

Last year, the reimbursement of homeopathy accounted for 126.8 million euros out of a total of about 20 billion for all drugs reimbursed, according to the Health Insurance.

The Boiron Group requests the suspension of its stock market price

The French group of homeopathy Boiron asked Thursday the suspension of its stock market, after the leak in the press of the final opinion of the High Authority of Health (HAS) on the evaluation of the medical benefit of homeopathic medicines. The HAS considered that homeopathy should no longer be reimbursed by Social Security because its effectiveness is not proven. Boiron, who himself was not informed of this opinion, denounced in a statement "a new violation of the rules of this evaluation procedure that seriously affects the company, its employees and shareholders."

A cancellation would be a blow for laboratories Boiron, the world leader in the market, which make 60% of its sales in France on reimbursable homeopathic products. In the event of a cancellation, the Lyon group anticipates a 50% drop in sales on its refundable products in the first year, then another 50% in the second year. According to the mayor of Lyon, Gerard Collomb, about a thousand jobs would be threatened in the region.

ref: europe1